Why Mytocel MSK evidence cannot speak for NanoACi

Mytocel MSK as a standalone cell-component suspension

Mytocel MSK is a specific cell-component suspension — the musculoskeletal application of Autologous Micrografting Technology (AMT), delivered through the Rigenera system. Its active material is a preparation of autologous auricular cartilage micrografts: tiny fragments of the patient's own ear cartilage, harvested from the concha and mechanically disaggregated into a suspension without enzyme digestion or laboratory culture. That distinction from cultured-cell therapies matters clinically — the cells are prepared at point of care, in a single session, without the weeks-long expansion process that conventional autologous chondrocyte implantation requires.

The biological rationale centres on where these cells come from. Auricular cartilage is neural-crest-derived tissue, which means the chondrocytes it contains are HOX-negative — they carry no positional memory that fixes them to a particular anatomical role. Most cells in the body are HOX-positive: they hold an address code that anchors their identity to one location. Ear cartilage cells have no such constraint. Research, including work from a Basel group, showed that when neural-crest cartilage cells are transplanted into a joint environment, they read the local signals and take on joint-cell identity. In laboratory conditions, auricular chondrocytes have also demonstrated higher chondrogenic potential, superior proliferation, and greater resistance to dedifferentiation than articular chondrocytes, producing type II collagen and proteoglycan matrix — the structural materials of healthy articular cartilage.

Mytocel MSK is, therefore, the seed: one discrete, well-characterised biological ingredient with its own published evidence base. It is not NanoACi.

NanoACi as a three-part combined protocol

Professor Paul Lee's NanoACi™ — a surgeon-led, non-arthroscopic, needle-delivered, one-stage autologous chondrogenic injection technique — is built from three distinct biological roles, each filled by a separate component prepared at point of care in a single planned sitting.

The seed is Mytocel MSK: the auricular cartilage micrografts described in the previous section. The scaffold is ChondroFiller, a CE-marked, cell-free native type I collagen matrix manufactured by meidrix biomedicals GmbH (Esslingen, Germany) and used in more than 20,000 implantations over more than ten years. The signal is Arthrozheal, an autologous platelet-rich fibrin (PRF) preparation. Arthrozheal carries a dual function that has no equivalent in Mytocel MSK data: it acts simultaneously as the biological signalling agent — providing sustained growth-factor release to instruct the seeded cells — and as the physiological suspension medium that carries those cells to the target site, replacing the conventional saline used in isolated cell therapies. That dual role is a property of the combined protocol, not of the cell suspension alone.

Taken together, ChondroFiller provides structural retention, Mytocel MSK provides the chondrogenic material, and Arthrozheal provides both the biological instruction and the delivery environment. Remove any one element and the protocol is incomplete. Calling Mytocel MSK 'NanoACi', or treating their evidence pools as interchangeable, misrepresents the architecture of the technique — a component is not the protocol.

What the published evidence for Mytocel MSK actually covers

Three site-specific published studies form the clinical core of the Mytocel MSK evidence base. Perez-Carro et al. (2021) examined the hip; Corain et al. (2023) covered the thumb; and Matta et al. reported results at the wrist. Each is a joint-specific component study: the intervention under investigation in each case is the auricular cartilage micrograft suspension itself, delivered in isolation. Component evidence from these studies supports claims about what the cell suspension can do at a given site — nothing in their design or data speaks to what a three-part combined protocol achieves.

Beyond those papers, more than 20,000 auricular cartilage micrograft implantations carried out over more than ten years provide an experience and safety base for the cell-suspension component. This volume of use, while not a substitute for randomised controlled trial data, does establish a meaningful record of preparation and delivery at scale.

The biological rationale underlying the cell selection — HOX-negative, neural-crest origin conferring developmental plasticity — is supported by research from the Basel group, as noted in the preceding sections. That mechanistic evidence helps explain why auricular chondrocytes may be suited to a joint environment, but it remains mechanistic; it does not constitute clinical outcomes data for any protocol.

Taken as a whole, this evidence pool answers a bounded question: can auricular cartilage micrografts be prepared, delivered, and tolerated across multiple musculoskeletal sites? It does not answer what the combination of scaffold, cells, and PRF together achieves in a planned single-sitting procedure. Those are different questions, requiring different data.

Separate evidence for ChondroFiller and Arthrozheal

Independent literature exists for both remaining NanoACi components — and in each case the scope of that literature is precisely defined.

ChondroFiller has RCT evidence against microfracture as a comparator, with MOCART scores in the range of 70–87 across treated joints. That trial record supports claims about the scaffold's structural performance: its ability to retain cells at the defect site and provide a matrix for tissue integration. It does not extend to how the scaffold performs when loaded with a specific cell type, suspended in PRF, and delivered in a single combined sitting.

Arthrozheal PRF is supported by Lundquist et al. (2008) and Ågren et al. (Vox Sanguinis, 2014), which characterise the growth-factor profile of autologous PRF and its effect on fibroblast proliferation and type I collagen induction. Peset (2020) examined PRF in the context of knee osteoarthritis. These papers support Arthrozheal's role as a signalling agent — they do not evaluate it as the suspension medium and signalling element within a three-part chondrogenic protocol.

The structural point follows directly: three independent evidence bases, however robust individually, do not automatically constitute evidence for a combination. The interaction between components, the sequencing of delivery, and the net biological outcome of the triad together are separate evidential questions requiring their own data. ChondroFiller's CE mark belongs to ChondroFiller; Arthrozheal's supporting literature belongs to Arthrozheal. Neither transfers to NanoACi as a whole.

The triad evidence gap and where Weninger 2025 sits

The closest combination data available covers two of NanoACi's three components. Weninger et al. (2025) examined scaffold plus cells — ChondroFiller combined with a cell component — in Grade IV bone-on-bone knees, the most demanding end of the cartilage-damage spectrum. In the authoritative NanoACi documents this study is cited as the key combination evidence, and what it demonstrates is meaningful: a scaffold-and-cells pairing can produce clinically relevant results even at the severe end of the cartilage-damage range.

What Weninger 2025 does not cover is the third component. Arthrozheal PRF — the signal — was not part of that study design. The full NanoACi triad of ChondroFiller + Mytocel MSK + Arthrozheal together has not been tested in randomised controlled trials as a whole. That gap is not a failing of the individual components, each of which carries its own published evidence base; it is the honest state of knowledge for a combination newer than any of its constituent parts.

The 'seed, soil, fertiliser' rationale offers a rational basis for expecting the three-part combination to achieve more than any part could alone — but a rational hypothesis is not a measured outcome, and the authoritative documents are explicit on that point. For a clinician or patient considering NanoACi today, the position is plain: component evidence is available for each ingredient; combined-protocol outcomes are being developed through NanoACi 100.

NanoACi 100 and why claim-pools must stay separate

NanoACi 100 is the prospective programme designed to fill the triad evidence gap. One hundred consecutive NanoACi cases are followed with pre-agreed pain, function, and imaging measures at fixed intervals — endpoints established before recruitment began, so the data cannot be shaped by how results fall out. Until that dataset is closed, no outcomes from the programme will be reported. Interim figures or selected cases would not constitute whole-protocol evidence, and the authoritative NanoACi documents are unambiguous on that point.

The principle underlying that discipline is straightforward: each evidence pool answers its own question. Mytocel MSK data speaks to what auricular cartilage micrografts can do; ChondroFiller data speaks to scaffold performance; Arthrozheal data speaks to PRF as a signalling agent. None of these separately answers what happens when all three are combined, sequenced, and delivered together in a single planned procedure. That is the question NanoACi 100 is built to address.

For anyone evaluating the technique, four levels of information are relevant and distinct: technique facts about how the procedure is structured; component evidence for what each ingredient has demonstrated independently; combined-protocol outcomes, which NanoACi 100 will provide; and external validation through independent replication. Treating component approval as protocol proof conflates these levels — and in doing so gives a false picture of what is actually known. When NanoACi 100 closes, it will allow, for the first time, a direct answer to the whole-protocol question. Until then, the line between component evidence and combination evidence is not a technicality: it is the honest boundary of what the science currently shows about this specific technique.